Canon Medical Systems acquires Swiss MRI research and development company Skope Magnetic Resonance Technologies AG

Published on:

Otawara Japan, November 26, 2019 - Canon Medical Systems Corporation (Headquarters:Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi) has concluded a contract to acquire all shares of Skope Magnetic Resonance Technologies AG (Headquarters: Zurich, Switzerland; CEO: Christoph Barmet). With a unique research and development team, Skope is a company devoted to providing MRI users with unprecedented imaging quality and performance. The acquisition of Skope was completed according to the required approval procedures.

Skope’s expertise in MRI sensorics, signal-processing and image reconstruction covers the entire chain from signal acquisition to image generation. As a result, reproducible image quality, great image detail and time-saving MRI scanning are achieved. Skope is equipping leading MRI research sites with its high-precision magnetic field monitoring systems and, sophisticated image reconstruction software to facilitate next-generation MR imaging and diagnostics.

Canon Medical Systems succeeded in developing and introducing the first Japanese MRI in1983, and has been devoting itself to research and development of innovative MRI technologies such as Pianissimo, Canon Medical’s unique acoustic noise reduction technology, providing extraordinary patient comfort.

Canon Medical Systems is welcoming the Skope team and will leverage its talent to promote advanced research and development of MRI systems, committing to innovative MRI solutions for uncompromised patient care.

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.